Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial

13th December 2019 Uncategorised 0

Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone

More: Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial
Source: News